Table 2.

Prevalence (%) of ADAMTS13 deficiency in patients clinically diagnosed with thrombotic thrombocytopenic purpura (TTP).

AuthorsPublication yearNo. patients% of patients with severe ADAMTS13 deficiency*% of patients with partial ADAMTS13 deficiency†
*Severe deficiency of ADAMTS13 activity denotes plasma levels of less than 10%. 
†Reduced ADAMTS13 activity denotes plasma levels below the lower limit of the laboratory reference interval (usually 40% to 140%). 
Furlan et al10/Tsai and Lian11  1998 37/30 94 100 
Veyradier et al (prospective cohort) 6 2001 66 71 89 
Mori et al17  2002 18 72 100 
Vesely et al(prospective cohort)18  2003 142 18 34 
Peyvandi et al.5  2004 100 48 72 
Coppo et al19  2004 46 67 80 
Zheng et al20 (prospective cohort) 2004 37 43 72 
AuthorsPublication yearNo. patients% of patients with severe ADAMTS13 deficiency*% of patients with partial ADAMTS13 deficiency†
*Severe deficiency of ADAMTS13 activity denotes plasma levels of less than 10%. 
†Reduced ADAMTS13 activity denotes plasma levels below the lower limit of the laboratory reference interval (usually 40% to 140%). 
Furlan et al10/Tsai and Lian11  1998 37/30 94 100 
Veyradier et al (prospective cohort) 6 2001 66 71 89 
Mori et al17  2002 18 72 100 
Vesely et al(prospective cohort)18  2003 142 18 34 
Peyvandi et al.5  2004 100 48 72 
Coppo et al19  2004 46 67 80 
Zheng et al20 (prospective cohort) 2004 37 43 72 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal